PI3K 抑制剂能否解乳腺癌内分泌治疗耐药的燃眉之急？以 PI3K 抑制剂为基础的联合治疗对于内分泌耐药人群的治疗前景如何？本文中，笔者与您一同来探讨这些问题，旨在为临床诊疗提供思路与启发。

中国医药卫生事业发展基金会乳腺肿瘤学组启动会于2025年3月1日在广州举行，雅康博董事长许军普、联席总裁张学华、副总裁付原等一行高管团队代表雅康博，作为支持方出席了本次活动。 中国医药卫生事业发展基金会是一家致力于推动中国医药卫生事业进步的 ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression, metabolic ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

一般来说，激素受体阳性乳腺癌出现pik3ca基因突变是比较后线的治疗了，也就是之前应该是用过很多轮治疗了，患者的体质也不是很好，对于pik3ca ...

The detection of the PIK3CA-H1047R variant is of paramount importance due to its close association with tumor growth and treatment resistance. Consequently, developing a straightforward, rapid, and ...